Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer. Website:
Twitter:
Facebook:
LinkedIn:
Dr. Backes on Rationale for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer
Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer. Website:
Twitter:
Facebook:
LinkedIn:
0 Comments